联合应用sIL-5Rα及sIL-13Rα2对支气管哮喘小鼠VCAM-1、STAT6水平的影响  

Effects of sIL-5Rα and sIL-13Rα2 on VCAM-1 and STAT6 in bronchial asthma mouse

作　　者：杨学敏[1] 史海广[1] 成家军[1] 李志奎[1] 

机构地区：[1]第四军医大学西京医院呼吸内科,西安710032

出　　处：《中华哮喘杂志（电子版）》2012年第1期15-18,共4页Chinese Journal of Asthma(Electronic Version)

基　　金：国家自然科学基金资助项目(30770926)

摘　　要：目的探讨联合应用可溶性白介素5受体α(sIL-5Rα)及可溶性白介素13受体α2(sIL-13Rα2)对支气管哮喘(简称哮喘)动物血管细胞黏附分子1(VCAM-1)、信号转导和转录激活因子6(STAT6)水平的影响。方法 50只BALB/c小鼠随机分为正常组、哮喘组、sIL-5Rα治疗组、sIL-13Rα2治疗组、联合sIL-5Rα及sIL-13Rα2治疗组(简称联合治疗组)。哮喘组和治疗组用鸡卵蛋白(OVA)和氢氧化铝致敏,用OVA激发,建立小鼠哮喘模型,正常组用生理盐水代替,其中sIL-5Rα治疗组、sIL-13Rα2治疗组及联合治疗组分别于诱发前30min给予腹腔注射100μgsIL-5Rα、sIL-13Rα2及联合应用sIL-5Rα及sIL-13Rα2各100μg,正常组和哮喘组激发前30min给予腹腔注射相同体积生理盐水。ELISA双抗体夹心法测定各组血清VCAM-1水平变化,免疫组织化学法和反转录-聚合酶链反应(RT-PCR)法检测各组小鼠肺组织STAT6水平变化。结果与正常组比较,哮喘组VCAM-1、STAT6含量明显升高(P<0.01);联合治疗组可有效降低VCAM-1、STAT6含量,与哮喘组比较差异有统计学意义(P<0.01);与单独治疗组相比,联合治疗组效果更明显(P<0.01)。结论联合应用sIL-5Rα及sIL-13Rα2可显著降低VCAM-1、STAT6含量,从而达到缓解和治疗哮喘的目的。Objective To investigate the effects of soluble interleukin-5 receptor α （sIL-5Rα） and soluble interleukin-13 receptorα2 （sIL-13Rα2） on VCAM-1 and STAT6 in bronchial asthma （asthma） animal. Methods A total of 50 BALB/c mice were randomly divided into 5 groups：the normal group, the asthmatic group, the sIL-5Rα treatment group, the sIL-13Rα2 treatment group, the combination of sIL-5Rα and sIL-13Rα2 treatment group （the combined treatment group）. Mice in the latter 4 groups were sensitized with ovalbumin （OVA） and Al （OH）3,and challenged with OVA to establish asthmatic models, while mice in the normal group were treated with saline. Mice in the sIL-5Rα treatment group, the sIL-13Rα2 treatment group and the combined treatment group were injected intraperitoneally with sIL-5Rα （100 μg）,sIL-13Rα （100 μg） and the combination of sIL-5Rα （100 μg） and sIL-13Rα2 （100 μg） 30 min before challenged,while mice in normal group and asthmatic group received saline. Then the VCAM-1 level of serum were measured by ELISA, and level of STAT6 were measured by immunohistochemically and RT-PCR.Results Compared with the normal group, the level of VCAM-1 and STAT6 in the asthmatic group were higher （P0.01）.Compared with the asthmatic group, the combined treatment group can effectively reduced VCAM-1 and STAT6 level （P0.01）.Compared with single treatment, combined treatment group were more effective （P0.01）.Conclusions sIL-5Rα and sIL-13Rα2 inhibit IL-5 and IL-13 functions can reduce VCAM-1 and STAT6 levels, which achieve the purpose of mitigation and treatment of asthma.

关 键 词：可溶性白介素5受体α 可溶性白介素13受体α2 血管细胞黏附分子1 信号转导和转录激活因子6 哮喘 

分 类 号：R734.2[医药卫生—肿瘤]